When you google " Parkinsons Dopamine Agonist Markety"You will be pleasantly surprised with the FACT that the market is 2.2 Billion dollars and is expect to be relatively flat for the next 10 years. Remember TTNP will do the same thing it is doing with Probuphine. That is take a generic drug and use the pronuera delivery system. I suspect that will be significantly easier to get through the FDA with this product. If you use conservative expectations of 15% market capture we are talking about more that 300 Million a year for just this indication. THe average pharma deal is currently 3.1-5/x sales this yields a value of nearly 1B USD for TTNP. Making it exceedingly undervalued.
Titan would get a royalty share, so not as significant as you pose, but certainly significant from where we are. Once ProB is approved getting an already approved delivery sytem for a well accepted drug like dopamine would be fairly easy I would think. Friggin' CRL.